Lidocaina Aguettant

Lidocaine Hydrochloride, the active ingredient in Lidocaina Aguettant, is a local anesthetic presented as a sterile solution for infiltration, intradermal and intravenous use. It provides rapid, reversible loss of sensation in targeted tissues and is employed to facilitate minor surgical, dental, dermatologic and regional anesthesia procedures.

GNH USA supplies Lidocaina Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides reliable logistics to meet global regulatory requirements.

Lidocaine Hydrochloride is used as a local anesthetic for procedures requiring temporary nerve block.

Minor surgical procedures: provides rapid loss of sensation to facilitate incision, excision or suturing with minimal discomfort. Dental procedures: numbs oral tissues to allow tooth extraction, cavity preparation or periodontal surgery without pain. Dermatologic procedures: anesthetizes skin for biopsies, excisions or laser treatments, improving patient tolerance. Intravenous regional anesthesia: blocks limb nerves when administered with a tourniquet, enabling surgery on the extremity without systemic analgesia.

Lidocaine Hydrochloride may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Transient burning or stinging at the injection site - Mild dizziness or light‑headedness - Nausea or vomiting - Localized swelling or erythema

Serious or Rare Side Effects: - Systemic toxicity presenting as seizures or cardiac arrhythmias - Severe allergic reactions including anaphylaxis - Methemoglobinemia causing cyanosis - Persistent numbness or motor weakness beyond the expected duration

When using Lidocaina Aguettant, several precautions should be observed to ensure patient safety and product integrity.

Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics Dose calculation: base total dose on patient weight and maximum recommended limits Cardiac monitoring: observe for signs of arrhythmia in patients with pre‑existing heart disease Use with caution in hepatic impairment: reduced metabolism may increase systemic exposure Avoid intravascular injection: aspirate before administration to prevent rapid systemic absorption Store at ambient temperature: keep below 25°C, protect from moisture and light in the original packaging

Lidocaine Hydrochloride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may potentiate cardiotoxic effects - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase plasma lidocaine concentrations

Moderate Interactions (Monitor Closely): - Beta‑blockers (e.g., propranolol): may enhance bradycardia when combined with lidocaine - Other local anesthetics: cumulative dosing can raise risk of systemic toxicity - Diuretics (e.g., furosemide): may reduce plasma protein binding, modestly increasing free lidocaine